Press release from Companies
Publicerat: 2021-12-14 08:53:25
COPENHAGEN – Curasight A/S ("Curasight" or "the Company"). In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transaction made in Curasight made by managerial employee.
The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted 13 December 2021.
The transaction comprise the following managerial employee;
| Name | Position | Aggregated volume | Price, DKK |
| Kirsten Drejer | Member of the Board of directors | 3,886 | 123,058.35 |
| Total | 3,886 | 123,058.35 |
Kirsten Drejer total holdings in Curasight A/S after the purchase of the shares is 3,886 shares.
This disclosure contains information that Curasight is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14 December.
For further information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.
